THE SHP-GCB-402 STUDY FOR GAUCHER DISEASE
If you have Gaucher disease, you may be able to participate in a clinical trial that is taking a deeper look into how the disease is treated. Read more to find out how you can get involved today!
ABOUT GAUCHER DISEASE AND THE SHP-GCB-402 STUDY
If you have type I Gaucher disease, glucocerebroside (a fatty substance) builds up in your body because you lack the enzyme glucocerebrosidase (GBC), which is needed to break it down. When this substance accumulates in your bone marrow, it leads to loss of bone density and possible broken bones, as well as extreme pain.
The SHP-GCB-402 study for Gaucher disease is evaluating the effect velaglucerase alfa (VPRIV®) has on bone pain and bone density in people with type I Gaucher disease. VPRIV® is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type I Gaucher disease. This study is designed to look at whether VPRIV® can reduce bone pain and protect bone density.
WHO CAN PARTICIPATE IN THE SHP-GCB-402 GAUCHER DISEASE STUDY?
We’re looking for 40 people to take part in this study. Each volunteer must meet at least the following criteria:
Other criteria may also apply
- Be between 18 and 65 years of age (inclusive)
- Have type I Gaucher disease
- Not have received enzyme replacement therapy or
substrate reduction therapy in the past year
- Not have received any osteoporosis-specific treatment in the past year
WHAT WILL PARTICIPANTS IN THE SHP-GCB-402 STUDY BE ASKED TO DO?
While receiving VPRIV®, participants will visit a study clinic approximately 14 times throughout the study. During the dosing period, these visits will be once every 3 months. The study medication will be administered as a 60-minute intravenous infusion (a drip) once every 2 weeks. The first 3 doses will be administered at a study clinic. All doses from thereon may be administered at the participant’s home by a member of the study team, if the study doctor (investigator) sees fit. Overall, participants will receive 51 infusions over the course of 102 weeks.
All study-related office visits, medical examinations, and study medication will be provided to qualified study participants at no cost to them.
DO PARTICIPANTS HAVE TO PAY TO JOIN?
No. VPRIV and all study-related assessments will be provided at no cost to you.
HOW SAFE IS THE STUDY MEDICATION?
As with most medications, some people may experience side effects. Also some unexpected side effects may occur.
WHY PARTICIPATE IN CLINICAL RESEARCH?
Clinical research helps discover whether treatments are safe and effective, and can help doctors find out what treatments work best for either specific illnesses or different kinds of patients. By asking specific questions, the study investigators test new medications or the effects of existing medications on specific disease symptoms.